Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Industry, Sector and Symbol
Industry Technical & System Software
Sub-IndustryN/A
SectorComputer and Technology
CIKN/A
Phone+1-250-7084272
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$463,000.00
Profitability
Miscellaneous
Employees39
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions
What is Aurinia Pharmaceuticals' stock symbol?
Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."
How were Aurinia Pharmaceuticals' earnings last quarter?
Aurinia Pharmaceuticals Inc (TSE:AUP) released its earnings results on Tuesday, March, 19th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.04. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.09 million. View Aurinia Pharmaceuticals' Earnings History.
When is Aurinia Pharmaceuticals' next earnings date?
What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.
Has Aurinia Pharmaceuticals been receiving favorable news coverage?
Press coverage about AUP stock has trended positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Aurinia Pharmaceuticals' key competitors?
Some companies that are related to Aurinia Pharmaceuticals include Iress (IRE), GB Group (GBG), Emis Group (EMIS), Computer Modelling Group (CMG), SDL (SDL), Absolute Software (ABT), Ideagen (IDEA), Dotdigital Group (DOTD), Wandisco (WAND), Microgen (MCGN), TECSYS (TCS), IDOX (IDOX), Oxford Metrics (OMG), Seeing Machines (SEE) and Eckoh (ECK).
What other stocks do shareholders of Aurinia Pharmaceuticals own?
Who are Aurinia Pharmaceuticals' key executives?
Aurinia Pharmaceuticals' management team includes the folowing people:
- Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 61)
- Mr. Michael R. Martin, Co-Founder & COO
- Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
- Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
- Dr. Neil Solomons M.D., Chief Medical Officer
How do I buy shares of Aurinia Pharmaceuticals?
Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Aurinia Pharmaceuticals' stock price today?
One share of AUP stock can currently be purchased for approximately C$9.04.
How big of a company is Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals has a market capitalization of C$829.81 million and generates C$463,000.00 in revenue each year. Aurinia Pharmaceuticals employs 39 workers across the globe.
What is Aurinia Pharmaceuticals' official website?
How can I contact Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.
MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days.
